SHANGHAI–(BUSINESS WIRE)– Effepharm Ltd lanceerde op creatieve wijze een merk-NMN-ingrediënt om het zuiverste en veiligste NMN-ingrediënt over de hele wereld te brengen. Het is klinisch bewezen dat UTHEVER® NMN veilig is en het NAD+/NADH-niveau in het menselijk lichaam verbetert, waardoor de anti-verouderingsfunctie wordt gerealiseerd.

Op 5 mei 2022 publiceerde Frontiers in Aging, een gezaghebbend internationaal tijdschrift over verouderingsmechanismen, een NMN klinisch onderzoeksrapport met nieuwe inzichten en meer ervaring op het gebied van een lang leven.

Frontiers in Aging, een van de grootste en meest geciteerde uitgevers ter wereld, onder leiding van en peer-reviewed door redacties van meer dan 100.000 toponderzoekers, stemden ermee in om het klinische onderzoeksrapport van UTHEVER® NMN te publiceren, dat werd beoordeeld door wetenschappers, waaronder professoren aan de Harvard Medical School. Dit is de eerste keer dat Effepharm gedetailleerde onderzoeksgegevens aan het publiek heeft vrijgegeven.

Effepharm’s UTHEVER® NMN: 66 people Human Clinical Trial Data Published, NAD+/NADH Level increased 38% in 2 months

SHANGHAI–(BUSINESS WIRE)– Effepharm Ltd creatively launched a branded NMN ingredient to bring the purest and safest NMN ingredient around the world. UTHEVER® NMN has been clinically proven to be safe and to improve the NAD+/NADH level in the human body, thus realizing the anti-aging function.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220607005649/en/

Figure 1 https://www.frontiersin.org/articles/10.3389/fragi.2922.851698/full (Graphic: Business Wire)

On 5th May 2022, Frontiers in Aging, an authoritative international journal on aging mechanisms, published one NMN clinical trial report with new insights and more experience being brought into the field of longevity.

Frontiers in Aging, one of the largest and highest-cited publishers in the world, led and peer-reviewed by editorial boards of over 100,000 top researchers, agreed to publish UTHEVER^® NMN’s human clinical trial report, which was reviewed by scientists, including professors at Harvard Medical School. This is the first time that Effepharm released detailed trial data to the public.

Compared with previous NMN clinical trials involving dozens of people, the number of Effepharm’s UTHEVER® clinical trial was up to 66 people which is more conspicuous. At the end of the study (day 60), the level of NAD+/NADH increased further by 38% from baseline in the UTHEVER® group, compared to a mere 14.3% rise in the placebo group which might be attributed to the placebo effect. HOMA (homeostatic model assessment), 6 minute walking endurance test and SF-36 questionnaire were assessed to show that UTHEVER® has the potential to improve the quality of life and boost the happiness of the subjects under the test conditions.

Moreover, Effepharm as one of the leading manufacturer of NMN, has finished the toxicology tests of Uthever, which proved that Uthever is non-mutagenic and has no acute and sub-chronic toxicity. Although the test results are not publicly available now, they have laid a solid foundation for the evaluation of the safety of UTHEVER^® NMN.

Effepharm’s R&D Director Jianjun Yu said: “ The clinical trials of UTHEVER® NMN is to establish a more professional and scientific image, helping the downstream supplement brand side get more power to do product endorsement and give more confidence to end consumers. Up to now, more and more well-known supplement brands such as Prohealth Longevity® in the USA, Do Not Age in UK, Kenay® Agescience, AFEGE Anti-aging Shop, MoleQlar in EU., VitaNAD+ in Japan etc. are using UTHEVER® trademark and realized the co-branding effects.”

Dr. Yu also revealed that the first period of NMN clinical trials mainly aimed to verify the safety of UTHEVER® NMN, so we designed a lower dosage to some extent. In the next few years, we will consider to conduct more NMN function researches to explore the safety of larger doses of NMN and the effectiveness of related indications on which this trial data are based. Effepharm Ltd will also apply for FDA Affirmed GRAS on NMN, which means that NMN raw material through the food regulations of various countries has taken a milestone step.

Reference:

https://www.frontiersin.org/articles/10.3389/fragi.2022.851698/full

View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005649/en/

Contacts

Effepharm Ltd

marketing@effepharm.com